Anika Therapeutics, Inc.
ANIKNASDAQHealthcare● Active
$14.60
+$0.12(+0.83%)
Market Cap$194262110
P/E Ratio—
52W High$16.24
52W Low$7.87
Anika Therapeutics, Inc. (ANIK) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ANIK · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.11B | $0.12B | $0.12B | $0.11B | $0.15B |
| Cost of Revenue | $0.05B | $0.04B | $0.04B | $0.04B | $0.06B |
| Gross Profit | $0.06B | $0.08B | $0.08B | $0.07B | $0.08B |
| Gross Margin %(computed) | 56.56% | 63.38% | 68.33% | 64.33% | 56.12% |
| Operating Expenses | |||||
| R&D Expenses | $0.03B | $0.03B | $0.02B | $0.02B | $0.03B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.07B | $0.08B | $0.08B | $0.07B | $0.08B |
| Operating Income | ($0.01B) | ($0.01B) | $0.00B | $0.00B | $0.00B |
| Operating Margin %(computed) | -9.80% | -4.25% | 0.70% | 3.22% | 1.77% |
| Interest Income | $0.00B | — | $0.00B | $0.00B | — |
| Interest Expense | $0.00B | — | $0.00B | $0.00B | — |
| Income Before Tax | ($0.01B) | ($0.00B) | $0.00B | $0.00B | $0.00B |
| Income Tax Expense | $0.00B | $0.01B | $0.01B | $0.00B | ($0.00B) |
| Net Income | ($0.01B) | ($0.06B) | ($0.08B) | ($0.01B) | $0.00B |
| Net Margin %(computed) | -9.64% | -47.02% | -68.44% | -13.05% | 2.80% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.76 | $-3.83 | $-5.64 | $-1.02 | $0.29 |
| Wtd Avg Shares | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B |
| EBITDA | ($0.01B) | $0.00B | $0.02B | $0.02B | ($0.00B) |
| EBITDA Margin %(computed) | -4.72% | 2.52% | 12.47% | 15.95% | -2.82% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Anika Therapeutics, Inc. data
About Anika Therapeutics, Inc. (ANIK) Income Statement
Anika Therapeutics, Inc. (ANIK) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ANIK reported revenue of $0.11B, gross profit of $0.06B (gross margin 56.56%), and net income of ($0.01B) — a net profit margin of -9.64%.
Frequently asked questions
ANIK · 4 questionsAnika Therapeutics, Inc. (ANIK) reported revenue of $0.11B for 2025, down 5.9% year-over-year.
ANIK revenueANIK salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09